2014
Genetic/familial high-risk assessment: breast and ovarian, version 1.2014.
Daly M, Pilarski R, Axilbund J, Buys S, Crawford B, Friedman S, Garber J, Horton C, Kaklamani V, Klein C, Kohlmann W, Kurian A, Litton J, Madlensky L, Marcom P, Merajver S, Offit K, Pal T, Pasche B, Reiser G, Shannon K, Swisher E, Voian N, Weitzel J, Whelan A, Wiesner G, Dwyer M, Kumar R. Genetic/familial high-risk assessment: breast and ovarian, version 1.2014. Journal Of The National Comprehensive Cancer Network 2014, 12: 1326-38. PMID: 25190698, DOI: 10.6004/jnccn.2014.0127.Peer-Reviewed Original ResearchConceptsNCCN GuidelinesAssessment of genetic mutationsGenetic/Familial High-Risk AssessmentDevelopment of breastManagement of patientsHamartoma tumor syndromeOvarian cancerGenetic aberrationsGenetic testing/counselingTumor syndromeIncreased riskGenetic mutationsHigh-risk assessmentDiagnostic criteriaBreastNCCNMutationsBRCA1/BRCA2Genetic/FamilialTP53PatientsSyndromeCancerCowdenGuidelines
1993
Ovarian cancer risk counseling: a guide for the practitioner.
Daly M, Lerman C. Ovarian cancer risk counseling: a guide for the practitioner. Oncology 1993, 7: 27-34; discussion 34, 37-8, 41. PMID: 8280574.Peer-Reviewed Original ResearchConceptsLong-term disease-free survivalStage III or IV diseaseDisease-free survivalEpithelial ovarian cancerEarly stage diseaseNon-specific symptomsIV diseaseImmunologic compromiseOvarian cancerStage diseaseGynecologic cancerChemotherapeutic approachesDiagnosed casesNatural historyPainful deathDiseaseCancerDeathUnited StatesPainPatientsMalnutritionYearsSurvivalSymptoms